Padcev Sales Exceed Expectations As Seattle Genetics Pursues Earlier Indications

 
• By Mandy Jackson

The bladder cancer drug delivered $34.5m in its first full quarter of sales – four times analyst consensus for Q1 – and Padcev’s market may grow rapidly based on results from ongoing studies.

Hitting bigger business target
Analysts raised their Padcev forecasts based on Q1 sales

More from New Products

More from Scrip